FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy

Puntos clave

• FAM168B is highlighted as a promising target for enhancing immune response against tumors.
• In vitro studies demonstrate that targeting FAM168B may improve T cell therapy effectiveness in cancer treatment.
• The approach focuses on using chimeric antigen receptors to enhance T cell-mediated tumor destruction.
• Results may support further research into FAM168B's role in the tumor microenvironment.